Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option

REDWOOD CITY, Calif., July 24, 2019 (GLOBE NEWSWIRE) — Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting metabolic and orphan diseases, announced today that Handok, Inc. (“Handok”) and Genexine, Inc. (“Genexine”), exercised their combined full …

Read more

Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option

REDWOOD CITY, Calif., July 24, 2019 (GLOBE NEWSWIRE) — Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting metabolic and orphan diseases, announced today that Handok, Inc. (“Handok”) and Genexine, Inc. (“Genexine”), exercised their combined full …

Read more